Harborside


Zynerba Pharmaceuticals, Inc.

ZYNE


Canadian symbol: ZYNE
US symbol: ZYNE

Currency in USD

Valuation Measures4

Market Cap (intraday) 39.81M
Enterprise Value -22.24M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)1.15k
Price/Book (mrq)0.70
Enterprise Value/Revenue 397.61
Enterprise Value/EBITDA 0.60

Trading Information

Stock Price History

Beta (5Y Monthly) 1.79
52-Week Change 3-81.00%
S&P500 52-Week Change 3-16.88%
52 Week High 34.6280
52 Week Low 30.8360
50-Day Moving Average 31.1658
200-Day Moving Average 31.7471

Share Statistics

Avg Vol (3 month) 3435.25k
Avg Vol (10 day) 3426.07k
Shares Outstanding 545.75M
Implied Shares Outstanding 6N/A
Float 841.89M
% Held by Insiders 14.06%
% Held by Institutions 124.59%
Shares Short (Aug 30, 2022) 4720.52k
Short Ratio (Aug 30, 2022) 41.42
Short % of Float (Aug 30, 2022) 41.64%
Short % of Shares Outstanding (Aug 30, 2022) 41.57%
Shares Short (prior month Jul 28, 2022) 4880.35k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2021
Most Recent Quarter (mrq)Jun 29, 2022

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-28.09%
Return on Equity (ttm)-52.08%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -36.88M
Net Income Avi to Common (ttm)-37.74M
Diluted EPS (ttm)-0.9620
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)62.49M
Total Cash Per Share (mrq)1.44
Total Debt (mrq)449.38k
Total Debt/Equity (mrq)0.79
Current Ratio (mrq)6.89
Book Value Per Share (mrq)1.38

Cash Flow Statement

Operating Cash Flow (ttm)-25.56M
Levered Free Cash Flow (ttm)-11.15M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
ZYNE
Zynerba Pharmaceuticals
1 month ago
ZYNE
Zynerba Pharmaceuticals
1 month ago
ZYNE
Zynerba Pharmaceuticals
2 months ago
ZYNE
Zynerba Pharmaceuticals
2 months ago
ZYNE
Zynerba Pharmaceuticals
2 months ago
ZYNE
Zynerba Pharmaceuticals
2 months ago
ZYNE
Zynerba Pharmaceuticals
7 months ago
ZYNE
Zynerba Pharmaceuticals
7 months ago
ZYNE
Zynerba Pharmaceuticals
10 months ago
ZYNE
Zynerba Pharmaceuticals
10 months ago
ZYNE
Zynerba Pharmaceuticals
10 months ago
ZYNE
Zynerba Pharmaceuticals
10 months ago
ZYNE
Zynerba Pharmaceuticals
11 months ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago

Currency in USD
Earnings EstimateCurrent Qtr. (Sep 2022)Next Qtr. (Dec 2022)Current Year (2022)Next Year (2023)
No. of Analysts5555
Avg. Estimate-0.23-0.22-0.9-0.82
Low Estimate-0.24-0.24-0.92-0.94
High Estimate-0.21-0.21-0.88-0.53
Year Ago EPS-0.26-0.22-0.95-0.9
Revenue EstimateCurrent Qtr. (Sep 2022)Next Qtr. (Dec 2022)Current Year (2022)Next Year (2023)
No. of Analysts5555
Avg. EstimateN/AN/AN/AN/A
Low EstimateN/AN/AN/AN/A
High EstimateN/AN/AN/AN/A
Year Ago SalesN/AN/AN/AN/A
Sales Growth (year/est)N/AN/AN/AN/A
Earnings History2021-09-292021-12-302022-03-302022-06-29
EPS Est.-0.25-0.26-0.23-0.23
EPS Actual-0.26-0.22-0.21-0.24
Difference-0.010.040.02-0.01
Surprise %-4.00%15.40%8.70%-4.30%
EPS TrendCurrent Qtr. (Sep 2022)Next Qtr. (Dec 2022)Current Year (2022)Next Year (2023)
Current Estimate-0.23-0.22-0.9-0.82
7 Days Ago-0.23-0.22-0.9-0.82
30 Days Ago-0.24-0.25-0.93-0.87
60 Days Ago-0.24-0.25-0.93-0.87
90 Days Ago-0.24-0.25-0.94-0.86
EPS RevisionsCurrent Qtr. (Sep 2022)Next Qtr. (Dec 2022)Current Year (2022)Next Year (2023)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 Days1111
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesZYNEIndustrySector(s)S&P 500
Current Qtr.11.50%N/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current Year5.30%N/AN/AN/A
Next Year8.90%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
4.06%% of Shares Held by All Insider
24.59%% of Shares Held by Institutions
25.63%% of Float Held by Institutions
64Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
ETF Managers Group, LLC2,447,407Jun 29, 20225.35%2,129,244
Vanguard Group, Inc. (The)1,946,590Jun 29, 20224.25%1,693,533
Mirae Asset Global Investments Co., Ltd.1,232,456Jun 29, 20222.69%1,072,236
Shaw D.E. & Co., Inc.1,109,155Jun 29, 20222.42%964,964
Blackrock Inc.843,683Jun 29, 20221.84%734,004
Renaissance Technologies, LLC736,600Jun 29, 20221.61%640,842
Geode Capital Management, LLC412,401Jun 29, 20220.90%358,788
Penserra Capital Management LLC349,336Jun 29, 20220.76%303,922
Millennium Management Llc303,551Jun 29, 20220.66%264,089
IQ EQ Fund Management (Ireland) Ltd224,221Jun 29, 20220.49%195,072
Davy Global Fund Management Ltd213,469Mar 30, 20220.49%185,718
Bridgeway Capital Management, Inc.165,900Jun 29, 20220.36%144,333

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
ETF Managers Tr-EFTMG Alternative Harvest ETF2,447,407Jun 29, 20225.35%2,129,244
Vanguard Total Stock Market Index Fund1,289,801Jun 29, 20222.82%1,122,126
Global X Fds-The Global X Cannabis ETF610,259Aug 30, 20221.33%530,925
Vanguard Extended Market Index Fund603,145Jun 29, 20221.32%524,736
Fidelity Extended Market Index Fund247,157Jun 29, 20220.54%215,026
Amplify Seymour Cannabis ETF212,298Apr 29, 20220.46%184,699
Bridgeway Funds Inc-Ultra Small Company Market Fund152,200Jun 29, 20220.33%132,414
ETF Series Solutions-Defiance Next Gen Altered Experience ETF137,038Jun 29, 20220.30%119,223
iShares Micro Cap ETF86,437Aug 30, 20220.19%75,200
Dimensional ETF Tr-Dimensional U.S. Small Cap ETF67,774Jan 30, 20220.16%58,963
Fidelity Total Market Index Fund56,274Jun 29, 20220.12%48,958
Fidelity Series Total Market Index Fund40,620Jun 29, 20220.09%35,339
Vanguard Balanced Index Fund37,481Jun 29, 20220.08%32,608
DFA U.S. Targeted Value Portfolio22,491Apr 29, 20220.05%19,567
Fidelity NASDAQ Composite Index Fund21,768Jun 29, 20220.05%18,938
Northern Small Cap Core Fund16,629Jun 29, 20220.04%14,467
Price (T.Rowe) U.S. Equities Trust18,200Mar 30, 20220.04%15,834
DFA U.S. Small Cap Series14,377Apr 29, 20220.03%12,507
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Zynerba Pharmaceuticals, Inc.


Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference

Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference

DEVON, Pa., Sept. 22, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the Ladenburg Thalmann ... Read More...
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium

DEVON, Pa., Sept. 08, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, announces an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium, being he... Read More...
Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference

Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference

DEVON, Pa., Sept. 06, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present in-person at the H.C. Wain... Read More...
Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 Announced positive topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) Company focusing resources on orphan neuropsychiatric disorde... Read More...
Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference

Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference

DEVON, Pa., Aug. 03, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present an overview and update of t... Read More...
Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

– The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments – – Safety data reinforce excellent tolerability profile of Zygel – – Company will focus resources on FXS and 22q development – – Cash runway extended through the end of 2023 / early 2024 – – Zynerba... Read More...
Zynerba Pharmaceuticals Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

– Poster presentation highlights design enhancements incorporated into pivotal RECONNECT trial – – Oral presentation demonstrates long-term safety and potential effectiveness of Zygel in children and adolescents with Fragile X syndrome – DEVON, Pa., June 01, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative ph... Read More...
Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights

– Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 – – Topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) expected mid-year 2022 – – $69.7 million in cash and cash equivalents at M... Read More...
Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting

– Data support the long-term safety and effectiveness of Zygel – – Greatest improvements seen in those with complete methylation of their FMR1 gene – DEVON, Pa., May 11, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsy... Read More...
Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting

Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting

DEVON, Pa., May 09, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podium presentation at the International Society for Autism Research Annual Meeting (INSAR 2022), being he... Read More...
Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting

DEVON, Pa., May 02, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting, held April 28-30, 2022, in New Orleans, La.... Read More...
Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting

Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting

DEVON, Pa., April 21, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting, being held Apri... Read More...
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

– European Commission granted orphan drug designation for Zygel™ in Fragile X syndrome (FXS) – – Continued enrollment in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with FXS; topline results expected second-half 2023 – – Completed enrollment in Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q... Read More...
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome

DEVON, Pa., Feb. 28, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the European Commission (EC) has granted orphan drug designation to cannabidiol, the active ingredient in it... Read More...
Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome

DEVON, Pa., Feb. 28, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the completion of enrollment for the 14-week Phase 2 INSPIRE (Assessing the Impact of Zygel on Pediatric Behavi... Read More...
Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer

Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer

DEVON, Pa., Feb. 15, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the appointment of Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, bio... Read More...
Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

– Company plans to focus development of Zygel™ in FXS, ASD and 22q – – Company plans to initiate Phase 3 trial with Zygel in ASD in the second half of 2022 – – Zynerba to hold conference call tomorrow, January 5, 2022 at 9:00 a.m. ET – DEVON, Pa., Jan. 04, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative phar... Read More...
Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium

Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium

DEVON, Pa., Dec. 06, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced presentation details for The BRAIN Foundation Synchrony 2021 Symposium, being held virtually December 11-12, 2021... Read More...
Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™

Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™

DEVON, Pa., Nov. 22, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the European Patent Office has issued Patent No. 3687513, titled “Treatment of Fragile X Syndrome and Autism... Read More...
Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October

Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October

DEVON, Pa., Oct. 21, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced oral and poster presentations at the Society for Developmental & Behavioral Pediatrics Annual Meeting, being ... Read More...
Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit

Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit

DEVON, Pa., Oct. 19, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan... Read More...
Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition

Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition

DEVON, Pa., Oct. 08, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 American Academy of Pediatrics (AAP) National Conference & Exhibitio... Read More...
Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

DEVON, Pa., Sept. 20, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during ... Read More...
Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Trial will evaluate the efficacy and safety of Zygel in children and adolescents with Fragile X Syndrome Topline results expected in second half of 2023 DEVON, Pa., Sept. 13, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n... Read More...
Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021

Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021

DEVON, Pa., Sept. 09, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today presented data from the Phase 2 BRIGHT trial describing tolerability and efficacy of Zygel (cannabidiol formulated in a tr... Read More...
Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

DEVON, Pa., Sept. 02, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during ... Read More...
Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights

On track to initiate RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, in the third quarter of 2021Positive feedback from FDA clarifies potential path forward in ASDCash runway well into the first half of 2024; $85.8 million at June 30, 2021 DEVON, Pa., Aug. 09, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), t... Read More...
Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference

Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference

DEVON, Pa., Aug. 04, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Company management will participate in a fireside chat during the Canaccord Genuity 41st Annual Growth Confe... Read More...
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference

Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference

DEVON, Pa., July 07, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the L... Read More...
Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting

Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting

DEVON, Pa., June 11, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster today at SLEEP 2021, the 35th Annual Meeting of the Associated Professional Sleep Societies, LLC. A copy of th... Read More...
Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting

Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting

– 46.4% of shares voted, quorum not established to hold annual meeting – – Meeting scheduled to reconvene June 29, 2021 at 9:00 AM EDT – – Company strongly encourages stockholders holding unvoted proxies to cast their votes – DEVON, Pa., June 09, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutical... Read More...
Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting

Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting

DEVON, Pa., June 04, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of a poster at SLEEP 2021, the 35th Annual Meeting of the Associated Prof... Read More...
Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

DEVON, Pa., June 03, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster today from 10:00 a.m. – 11:00 a.m. ET in poster session II at the 2021 American Society of Clinical Psycho... Read More...
Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

DEVON, Pa., May 27, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of a poster at the 2021 American Society of Clinical Psychopharmacology (A... Read More...
Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

DEVON, Pa., May 26, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Je... Read More...
Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights

– RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, expected to be initiated in the third quarter of 2021 – – Cash runway well into first half 2024; $93.1 million at March 31, 2021 – DEVON, Pa., May 12, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transderma... Read More...
Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel™ in Fragile X Syndrome

- Confirmatory pivotal trial expected to be initiated in the third quarter of 2021 - - Zynerba to hold conference call today, May 5, 2021 at 5:30 pm ET - DEVON, Pa., May 05, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neur... Read More...
Zynerba Pharmaceuticals Presents Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting

Zynerba Pharmaceuticals Presents Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting

DEVON, Pa., April 29, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. Both posters will be made availab... Read More...
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting

Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting

DEVON, Pa., April 15, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtu... Read More...
Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference

Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference

DEVON, Pa., April 06, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of Zynerba, will present a company overview during the 20th Annual N... Read More...
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

DEVON, Pa., March 10, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of recen... Read More...
Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference

Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference

DEVON, Pa., March 04, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Company management will participate in the 33rd Annual ROTH Conference, which will be held virtually on Mar... Read More...
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome

- Single Trial to be Conducted in Patients with Fragile X Syndrome to Confirm Positive Results Seen in the Population of Responders in the CONNECT-FX Trial -- Conference Call and Webcast Today, December 17, 2020 at 8:30 am ET - DEVON, Pa., Dec. 17, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutica... Read More...
Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES)

Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES)

- New Efficacy Data Describe Strong Evidence of Seizure Reduction over 12 Months of Treatment, Including a 73% Median Reduction from Baseline in Monthly Seizure Frequency at Month 12 -- Zygel™ Improves the Profound Sleep Disturbance Often Experienced by Developmental and Epileptic Encephalopathy (DEE) Patients Enrolled in the BELIEVE Tria... Read More...
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy Society (AES)

Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy Society (AES)

DEVON, Pa., Nov. 23, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today has announced the acceptance and presentation details of two posters at the 2020 virtual annual meeting of the American Epil... Read More...
Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights

DEVON, Pa., Nov. 09, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the third quarter ended September 30, 2020, and provided an overview of recent operational hi... Read More...
Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting

Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting

DEVON, Pa., Oct. 15, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster describing data from the CONNECT-FX (Clinical study Of CaNNabidiol (CBD) in ChildrEn and AdolesCenTs with F... Read More...
New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder (ASD) Presented at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting

New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder (ASD) Presented at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting

DEVON, Pa., Oct. 15, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster describing data from the Phase 2 BRIGHT (An Open-Label Tolerability and Efficacy Study of ZYN002 Administer... Read More...
Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting

Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting

DEVON, Pa., Oct. 08, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and oral presentation details of two sets of data at the virtual American Academy of Child and Adol... Read More...
Coming Soon.

Delayed data (1h)


Share this page